Table 3 Prospective evolution of musculoskeletal outcomes over 12Â months of follow-up, according to extra-musculoskeletal manifestations in SpA patients
EMM | Baseline | 3Â months | 6Â months | 12Â months | p |
|---|---|---|---|---|---|
 Remission or inactive disease (ASDAS < 1.3) | |||||
 rAAU, n (%) | 12 (26.7%) | 14 (32.6%) | 13 (31.7%) | 12 (31.5%) | 0.92 |
 Psoriasis, n (%) | 10 (17.2%) | 9 (17.3%) | 10 (19.6%) | 11 (22%) | 0.7 |
IBD, n (%) | 0 | 1 (6.7%) | 2 (13.3%) | 1 (6.7%) | 0.07 |
Low disease activity (1.3 ≤ ASDAS < 2.1) | |||||
 rAAU, n (%) | 6 (13.3%) | 8 (18.6%) | 11 (26.8%) | 7 (18.4%) | 0.23 |
 Psoriasis, n (%) | 9 (15.5%) | 6 (11.5%) | 19 (37.2%) | 17 (34%) | 0.08 |
 IBD, n (%) | 1 (7.1%) | 3 (20%) | 4 (26.7%) | 5 (33.3%) | 0.27 |
High or very high disease activity (ASDAS ≥ 2.1) | |||||
 rAAU, n (%) | 27 (60%) | 21 (48.8%) | 17 (41.4%) | 19 (50%) | 0.08 |
 Psoriasis, n (%) | 39 (67.2%) | 37 (71.1%) | 22 (43.1%) | 22 (44%) | 0.02 |
 IBD, n (%) | 13 (92.8%) | 10 (66.6%) | 9 (60%) | 9 (60%) | 0.06 |